In from SCIREQ Team

Targetting COVID-19 Symptoms

 

At this stage in the COVID-19 pandemic, worldwide efforts are underway investigating potential vaccines and fast-tracking clinical trials, in an effort to contain the SARS-CoV-2 virus, coordinated by the WHO. One group in Montreal has taken an alternate approach, targetting the symptoms and inflammatory response rather than the virus itself, to reduce hospitalizations and mortality rates, while the vaccine research continues.

Dr. Price and his team from the Montreal Heart Institute are investigating the anti-inflammatory drug, colchicine to mitigate the cytokine storm created by SARS-CoV-2. This is in very early stages and the study called COLCORONA, is currently recruiting volunteers, expecting to have an indication of its efficacy within three months.

Given that this treatment is already FDA approved and readily available, if it mitigates the inflammation caused by the immune system and helps avoid the serious complications of COVID-19, it will be a great step forward to reduce the serious effects of this pandemic.

Recent Posts